Apollo Hospitals Enterprise Limited Overview
Apollo Hospitals Enterprise is India's largest private healthcare group by revenue and the country's most vertically integrated one. It spans tertiary and quaternary hospitals, India's largest retail pharmacy network (7,100+ stores), India's largest pharmaceutical wholesale supply chain (through the pending Keimed combination), the Apollo 24/7 digital platform, and an out-of-hospital network of clinics, diagnostics, day-surgery, dialysis and dental formats. The hospital business, about 50% of revenue, is the profit and cash engine: roughly 24% EBITDA margins and 25%+ ROCE. The pharmacy and digital arm drives scale and patient acquisition at thin but improving margins. Apollo's moat is brand, clinical depth in complex specialties, and an integrated care pathway. The group is mid-way through a structural reset: it is demerging pharmacy and digital into Apollo Healthtech Limited (listing targeted for Q4 FY27) while running its largest-ever hospital capacity build (about 5,800 beds over five years). That will leave AHEL as a hospital-centric compounder holding a 15% stake in the pharmacy/digital vehicle.
What the company does
AHEL operates a pan-India network of multi-specialty and super-specialty hospitals. As of Q3 FY26 this comprised 76 hospitals with about 9,561 operational beds including managed facilities (FundsIndia equity research desk). Owned-and-operated census beds excluding AHLL and managed beds were 8,131 at end-FY26 and 8,352 at 30 June 2026, with 70% group occupancy in Q1 FY27 (company Q1 FY27 disclosures via Omnicuris/IPP). Around the hospitals sit two businesses that are housed in subsidiaries and consolidated:
-
Apollo HealthCo Limited (AHL) — omnichannel pharmacy distribution (back-end supply to the 7,100+ Apollo Pharmacy stores, owned by the separately held front-end company Apollo Pharmacies Ltd) and the Apollo 24/7 digital platform (teleconsultation, e-pharmacy, diagnostics booking, insurance distribution). FY26 revenue: INR 10,808 crore, the first year above INR 10,000 crore.
-
Apollo Health and Lifestyle Limited (AHLL) — retail healthcare and diagnostics: Apollo Clinics, Apollo Diagnostics, Apollo Sugar, Apollo Spectra (short-stay surgery), Apollo Dialysis and Apollo White Dental. Apollo Cradle (maternity) and Apollo Fertility are being divested to Cloudnine. FY26 revenue: INR 1,865 crore. AHLL became a 100% subsidiary in April 2026 after the IFC stake buyout.
Business and revenue model
| Revenue stream | Model type | Primary payor / customer | Approximate share of FY26 consolidated revenue (derived) |
|---|---|---|---|
| Inpatient and outpatient hospital services | Fee-for-service (episodic) | Self-pay (cash), private insurance/TPA, corporates, government schemes (CGHS/ECHS/PMJAY/state), international patients | 50% (INR 12,555 crore) |
| Pharmacy distribution (offline back-end) | Product distribution / trading | Apollo Pharmacies Ltd front-end stores (B2B intra-group) and, post-Keimed, third-party pharmacies | Majority of the 43% HealthCo share |
| Apollo 24/7 digital | Platform / marketplace (GMV-based take rates), consultation fees, insurance commissions | Consumers, insurers | Small (online pharmacy distribution revenue was INR 326 crore in Q2 FY26) |
| Diagnostics and retail health (AHLL) | Fee-for-service, B2C retail | Consumers, corporates, referral doctors | 7% (INR 1,865 crore) |
Apollo is overwhelmingly a service business (hospitals, clinics, diagnostics) with a large product-distribution adjunct (pharmacy). It has no material licensing or subscription revenue. Health-check packages (ProHealth) and Apollo 24/7 memberships are quasi-subscription but not separately disclosed.
Payor mix. In Q4 FY25, cash and insurance patients contributed about 83% of inpatient revenue, and revenue from that segment grew 11% YoY (ICICI Direct Q4 FY25 note). International patients are a meaningful high-ARPOB cohort. Bangladesh historically accounted for about 30% of international revenue but only about 2% of total revenue (ICICI Direct Q1 FY25).
Value-chain position
Apollo sits at the care-delivery end of the healthcare value chain (hospitals, clinics, diagnostics) and the distribution/retail end of the pharmaceutical chain (wholesale distribution via Keimed, retail via Apollo Pharmacy, online via 24/7). It does not manufacture drugs or devices at scale. Its private-label Apollo-branded FMCG/OTC range is sourced from contract manufacturers; private label was about 16% of pharmacy revenue in Q1 FY25 per the earnings call. Integration lets Apollo capture margin across referral (24/7, clinics) → diagnosis (AHLL) → intervention (hospitals) → chronic medication (pharmacy).
Company's own description vs. independent characterisation
The company describes itself in investor communications as India's first corporate hospital and Asia's foremost integrated healthcare provider, present across hospitals, pharmacies, primary care and diagnostic clinics, and multiple retail health formats (Screener company profile, drawing on company material). Management frames the current strategy as moving from episodic treatment to a continuum connecting prevention, early diagnosis, advanced intervention and long-term care (Q1 FY27 commentary, IPP, Aug 2026).
Independent characterisation. On economic substance Apollo is two businesses joined by a brand:
-
a high-return, capital-intensive hospital operator — about 24% EBITDA margin, ROCE 25–28%, ARPP of about INR 1.73 lakh per inpatient in Q2 FY26, the same profile as Max/Fortis/Medanta;
-
a low-margin, high-volume pharmacy distribution and consumer-health platform — HealthCo EBITDA margin 5.8% in Q1 FY27, which compares with pharmacy retailers and distributors such as MedPlus and Entero.
The consolidated 15% EBITDA margin understates hospital quality and overstates platform profitability. This blend is why the HealthCo demerger is the defining corporate event of FY27.
End-markets served
| End-market | Apollo vehicle | Geography |
|---|---|---|
| Tertiary/quaternary hospital care (cardiac, oncology, neuro, gastro, ortho, transplant) | AHEL and hospital subsidiaries (e.g., Apollo Multispeciality Hospitals, Kolkata) | India, with metros the core |
| Medical value travel | AHEL International Patient Services | Patients from South Asia, Africa, Middle East, South-East Asia |
| Retail pharmacy and pharma wholesale distribution | Apollo HealthCo / Apollo Pharmacies / Keimed | Pan-India; 19,000+ pincodes online |
| Digital health | Apollo 24/7 | Pan-India; 46 million users (Basis Point Insight, Mar 2026) |
| Diagnostics and ambulatory care | AHLL | Pan-India; 3,328 out-of-hospital touchpoints (Q3 FY26) |
| Health insurance distribution | Apollo 24/7 (insurance distribution started FY25) | India |
Strategy
Stated strategic themes (paraphrased from FY26–Q1 FY27 communications)
-
Hospital capacity and complexity. Add about 5,800 beds over five years (about INR 11,150 crore capex), focused on metros and the CONGO specialties (Cardiac, Oncology, Neuro, Gastro, Ortho) plus transplants. Push a higher share of complex procedures and international patients.
-
Value unlocking through simplification. Demerge and list omnichannel pharmacy and digital as Apollo Healthtech; take AHLL to 100% ownership; exit non-core verticals (Cradle and Fertility to Cloudnine); merge Apollo Hospitals North into AHEL.
-
Care continuum. Management frames growth around non-communicable diseases and moving from episodic treatment to prevention, early diagnosis, intervention and chronic care.
-
Digital profitability. Apollo 24/7 reached cash breakeven around Q1 FY27; full breakeven including ESOP costs targeted for Q3 FY27.
-
Capital efficiency. HCS ROCE of 25–28%; consolidated ROCE 23.7%; AAA credit profile.
Initiative register (last 24 months)
| Date | Initiative | Detail / target |
|---|---|---|
| Apr 2024 | Advent investment in Apollo HealthCo | INR 2,475 crore CCPS (12.1%); funds Keimed integration and digital |
| May 2025 | Board-approved hospital expansion plan | Bengaluru 700 beds; Gurgaon 510; Pune 400; Sonarpur 270; Hyderabad brownfield; earlier framing about 4,300 beds / INR 7,600 crore |
| Jun 2025 | Composite Scheme for Apollo Healthtech | Demerger plus Keimed merger; AHEL retains 15%; swap ratio 195.2 AHTL shares per 100 AHEL shares |
| Sep 2025 | AHLL full ownership | INR 1,254 crore to IFC; completed Apr 2026 |
| Sep 2025 | Gurugram proton oncology centre | 100 beds; INR 570 crore; about 4-year build; Apollo's third proton facility |
| FY25–FY26 | Apollo 24/7 cost programme | 24/7 costs cut about 20% YoY in Q1 FY26; quarterly cost INR 124 crore in Q3 FY26 (incl. INR 38 crore ESOP), down from INR 141 crore; digital cash loss INR 10 crore in Q1 FY27 |
| FY25 | AHLL cost programme | About INR 60 crore cost reduction cited by Q2 FY26 |
| FY26 | Four new hospitals | About 855 beds |
| May 2026 | Cloudnine combination | Cradle and Fertility valued at INR 1,550 crore (cash plus 9.9% of combined entity) |
| May 2026 | Merger of Apollo Hospitals North into AHEL | NCLT route; 10–12 months |
| Aug 2026 | 5,800-bed five-year plan | About INR 11,150 crore capex |
| ESG | Sustainability commitments | See Section 20 |
Management medium-term targets and guidance
| Guidance item | Target | Source |
|---|---|---|
| FY27 Healthcare Services revenue growth | About 18–20% (existing hospitals 13–14%, new hospitals about 7%) | Q1 FY27 call (Quartr; Stockgro) |
| FY27 Healthcare Services EBITDA margin | At least +100 bps improvement | Q4 FY26 call |
| Apollo HealthCo / AHTL annualised revenue run-rate | INR 25,000 crore by Q4 FY27 | Q4 FY26 and Q1 FY27 calls |
| AHTL exit EBITDA margin | 6.5–7.0% by end-FY27 | Q4 FY26 and Q1 FY27 calls |
| Apollo 24/7 / insurance breakeven | Full breakeven (incl. ESOP) by Q3 FY27 | Q1 FY27 call |
| AHTL listing | Q4 FY27 (Jan–Mar 2027) | Company; Sahi; Multibagg |
| Gurugram hospital commissioning | Q3 FY27 | Q1 FY27 release |
| Bed additions | About 5,800 over five years | Q1 FY27 release |
Products & Services
Pricing is generally not publicly disclosed at the catalogue level. Hospital tariffs vary by city, room category and payor contract.
Healthcare Services (Hospitals)
| Offering | Description and capabilities | Target customer | Launch / latest | Pricing model | Flagship examples |
|---|---|---|---|---|---|
| Cardiac Sciences | Cardiology, interventional cardiology, CABG, valve, structural heart, heart transplant | Insured and self-pay adults; international | Since 1983 | Package and itemised fee-for-service | Apollo Chennai, Indraprastha Delhi, Jubilee Hills Hyderabad |
| Oncology | Medical, surgical and radiation oncology; proton therapy; bone-marrow transplant | Cancer patients across payors; international | Proton: Jan 2019 (Chennai); Gurugram proton centre announced Sep 2025, about 4-year build | Fee-for-service and packages; drug pricing subject to NPPA trade-margin caps | Apollo Proton Cancer Centre, Chennai; Apollo Cancer Centres network |
| Neurosciences | Neurosurgery, stroke, epilepsy, spine | Adults/children | Ongoing | Fee-for-service | Pan-network |
| Gastroenterology and hepatology | Endoscopy, GI surgery, liver transplant | Adults/children | Ongoing | Fee-for-service/packages | Chennai, Delhi, Hyderabad |
| Orthopaedics | Joint replacement, sports medicine, robotic arthroplasty | Adults | Ongoing | Packages; knee implant prices regulated by NPPA ceiling | Pan-network |
| Transplant programme | Kidney, liver, heart, lung, multi-organ; green-corridor coordination | Complex end-stage disease | Ongoing; multi-organ green-corridor cases reported Q4 FY26 | Packages | Chennai, Delhi, Hyderabad, Bengaluru, Navi Mumbai, Lucknow |
| Robotic and minimally invasive surgery | Robotic urology, gynaecology, GI, ortho | Elective surgical | Ongoing | Fee-for-service | Pan-network |
| Critical care | ICU, NICU/PICU, emergency/trauma | All payors | Ongoing | Per-day plus procedures | Pan-network |
| International Patient Services | Concierge, visa, interpretation, packages for overseas patients | Africa, Middle East, South-East Asia, SAARC | Ongoing | Packages | Hospital-agnostic |
| ProHealth / preventive health checks | Personalised preventive programmes, AI risk scoring | Corporates, individuals | ProHealth programme relaunched about 2018–2023 | Fixed-price packages | All hospitals |
| Remote TeleHealth | Teleconsultation, tele-radiology, rural telemedicine, govt partnerships | Govt, corporates, remote populations | Since 2000 | Contract/fee | To be demerged into AHTL |
| O&M / project consultancy | Managing third-party hospitals | Hospital owners | Ongoing | Management fees | 6 managed hospitals, 790 beds (Screener) |
| Medical education | Nursing, allied health, academic programmes | Students | Ongoing | Tuition | Apollo academic institutions; not a reported segment |
| Healthcare Services KPI | Q4FY25 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
| Census beds owned excl. AHLL and managed (number) | 8,025 | — | 8,072 | 8,131 | 8,352 |
| Group occupancy (%) | 67 | 69 | 67 | 68 | 70 |
| ARPOB (INR per day) | 63,569 | — | — | — | — |
| ARPP (INR per inpatient) | — | 173,318 | — | — | — |
| HCS ROCE (%) | — | — | — | 25.4 | 28.5 |
Operating KPIs.
Digital Health & Pharmacy Distribution (Apollo HealthCo)
| Offering | Description | Target customer | Latest data point | Pricing / model |
|---|---|---|---|---|
| Offline pharmacy distribution | Back-end supply of pharma, OTC, private-label and FMCG to Apollo Pharmacy stores | Apollo Pharmacies Ltd (front-end) | Q2 FY26 revenue INR 2,335 crore (+16%); Q4 FY26 distribution EBITDA INR 195 crore (+20%) | Distribution margin |
| Apollo Pharmacy network (front-end, Apollo Pharmacies Ltd) | India's largest pharmacy retail chain | Retail consumers | 7,100+ stores (Mar 2026); 7,113 at Q3 FY26 | Retail MRP-based |
| Apollo 24/7 online pharmacy | E-pharmacy with quick delivery | Consumers in 19,000+ pincodes | Q2 FY26 online distribution revenue INR 326 crore (+22%) | Retail MRP less discounts |
| Apollo 24/7 teleconsultation | Video/chat consults with Apollo doctors | Consumers | Platform GMV INR 528 crore in Q4 FY26 (+20%) | Per-consult fee |
| Apollo 24/7 diagnostics marketplace | Home sample collection, lab booking | Consumers | Expanded to 18 new cities (Q2 FY26) | Per-test |
| Insurance distribution | Health insurance sold via the platform | Consumers | Started FY25; breakeven targeted Q3 FY27 | Commission |
| Private label (Apollo brand) | OTC, nutrition, personal care | Consumers | About 16% of pharmacy revenue (Q1 FY25) | Retail |
| Apollo 24/7 Circle (membership) | Loyalty/benefits programme | Repeat customers | — | Membership fee |
| Keimed wholesale distribution (post-scheme) | Wholesale pharma distribution with about 100 distribution centres serving 70,000+ pharmacies | Independent pharmacies, hospitals | About 15% share of India medicine distribution (Outlook Business) | Wholesale margin |
User base: 46 million Apollo 24/7 users (Basis Point Insight, Mar 2026). Platform GMV disclosures are inconsistent: one release cites INR 723 crore for Q2 FY26 against INR 528 crore for Q4 FY26, likely different GMV definitions. This is flagged.
Retail Health & Diagnostics (AHLL)
| Brand / vertical | Description | Status |
|---|---|---|
| Apollo Clinics | Multi-specialty primary-care clinics | Core; scaling |
| Apollo Diagnostics | Pathology labs and collection centres | Fastest-growing (+52% YoY in Q4 FY26); expanded tests (fetal chromosomal screening, genetic testing, extended HPV genotyping, whole genome sequencing) |
| Apollo Sugar | Diabetes management clinics | Core |
| Apollo Spectra | Short-stay surgical hospitals (ambulatory) | Core |
| Apollo Dialysis | Dialysis centres | Core |
| Apollo White Dental | Dental chain | Core |
| Apollo Cradle | Maternity and newborn hospitals: 12 centres in Hyderabad, Bengaluru, Chennai, Delhi NCR, Punjab | Being combined into Cloudnine (announced 20 May 2026) |
| Apollo Fertility | IVF/fertility centres (about 20 units per media) | Being combined into Cloudnine |
AHLL operated 3,328 out-of-hospital touchpoints at Q3 FY26.
Financial Narrative
Income statement
Sources and notes:
-
Revenue: company releases and Chola/Screener (FY22 INR 14,662.6 crore; FY23 INR 16,612.5 crore; FY24 INR 19,059.2 crore; FY25 INR 21,794 crore; FY26 INR 25,229 crore). FY21 base was INR 10,560 crore.
-
PAT: Stockezee/Screener; FY26 per company. EPS basic FY22–FY25 from Screener. FY26 basic is derived (INR 1,942 crore / 143.78 million shares); FY26 diluted INR 134.95 per IndiaMedToday.
-
FY22 PAT included one-off gains linked to restructuring (exceptional items). Underlying FY22 profit was lower.
-
FY24 EBITDA is derived from FY25 reported INR 3,022 crore and +26%.
Gross profit: Apollo reports under Ind AS by nature of expense and does not disclose gross profit. Simply Wall St computes TTM gross profit of about INR 8,300 crore on INR 24,220 crore revenue (about 34%); this is a third-party construct.
-
Quarterly PBT (before exceptional items) for FY26 was INR 569 crore (Q1), INR 668 crore (Q2) and INR 686 crore (Q3) per 5paisa.
-
DPS: FY24 = INR 6 interim + INR 10 final; FY25 = INR 9 interim + INR 10 final; FY26 = INR 10 interim + INR 10 final (total FY26 payout INR 287.6 crore).
Revenue CAGR. FY22–FY26 (4 years) is 14.5% (derived). FY21–FY26 (5 years, from INR 10,560 crore) is 19.0% (derived), inflated by the COVID-depressed FY21 base.
Commentary. Revenue has compounded at a steady 13–16% for four years. The real inflection is in profitability: consolidated EBITDA margin expanded about 230 bps from FY24 to FY26 and PAT grew 61% in FY25 and 34% in FY26. Three drivers stand out:
-
Apollo 24/7 cost reduction: digital cash loss fell to INR 10 crore in Q1 FY27 against losses above INR 140 crore a quarter in FY25.
-
Operating leverage in pharmacy distribution.
-
Steady hospital margins of about 24% despite new-unit start-up losses (INR 41 crore in Q4 FY26).
FY23–FY24 were margin-trough years as 24/7 investment peaked; FY25–FY26 show the payoff.
Balance sheet
Sources and discrepancies:
-
Total assets and PP&E: Stockopedia (INR million, converted). Goodwill, cash, receivables, inventory and lease-inclusive debt: stockanalysis.com. Borrowings excluding leases, net debt excluding leases and NWC: Stockezee. Shareholders' funds and minority interest: MarketsMojo.
-
MarketsMojo shows FY26 long-term borrowings of INR 2,705 crore against Stockezee's INR 2,430 crore (FY25: INR 4,754 crore vs INR 4,417 crore). Total borrowings agree at INR 5,658–5,659 crore.
-
The FY26 jump in short-term borrowings (INR 858 crore to INR 3,228 crore) mainly reflects reclassification of long-term debt into the current portion. Stockanalysis shows current portion of long-term debt at about INR 3,228 crore. This implies a meaningful FY27 refinancing need.
Commentary. Leverage rose in FY25: borrowings excluding leases climbed from INR 3,162 crore to INR 5,275 crore to fund hospital asset acquisitions (Pune, Kolkata Sonarpur, Gurgaon, Bengaluru) and AHLL/HealthCo needs. Leverage then stabilised in FY26 despite the INR 1,254 crore IFC buyout of AHLL, helped by 34% higher operating cash flow. Equity has compounded about 14% a year. Advent's INR 2,475 crore CCPS in Apollo HealthCo is treated as equity by CRISIL, which cushions group gearing.
Cash flow
Source: stockanalysis.com (INR million, converted). Stockezee reports FY22 OCF of INR 1,616 crore against stockanalysis' INR 1,696 crore. Capex is derived as OCF minus FCF. Dividends paid are derived from per-share cash payouts in each fiscal year × 143.78 million shares. No buyback has been announced or executed in the period.
Commentary. OCF rose 34% in FY26 to INR 2,856 crore, a cash conversion of about 76% of EBITDA. FCF is thin relative to profits because Apollo is in a heavy capex phase (INR 1,700–2,000 crore a year). Capex will step up under the 5,800-bed plan (about INR 11,150 crore over five years, roughly INR 2,200 crore a year before acquisitions). CRISIL expects AHEL's standalone cash surplus to run at INR 1,800–2,000 crore a year, enough to fund most expansion internally.
Ratios
ROE, ROA, gearing, coverage and turnover are derived from the tables above; FY22 ROA uses closing assets. ROIC is not disclosed by the company; consolidated ROCE excluding capital work-in-progress is the closest proxy (20% in FY24 to 23.7% in FY26, company release via ScanX). CRISIL estimated FY26 net debt/EBITDA at about 1.1x on its own adjusted basis. The negative cash conversion cycle reflects supplier credit in pharmacy distribution exceeding receivable days on insurer/government payors.
Commentary. Returns have re-rated sharply. ROE moved from about 14% in FY23–24 to 22% in FY26 as 24/7 losses fell and hospital ROCE climbed. Interest coverage nearly doubled. Gearing remains moderate and is on the AAA trajectory recognised by ICRA. The main watch-point is the FY26 shift of about INR 2,400 crore of debt into current maturities, a refinancing rather than solvency issue given AAA/A1+ access.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (Reported Label) Overview
| Segment (reported label) | Operating vehicle | Contents |
|---|---|---|
Healthcare Services (HCS) | AHEL standalone plus hospital subsidiaries/JVs (e.g., Apollo Multispeciality Hospitals, Apollo Hospitals North, Apollomedics Lucknow; associate Indraprastha Medical Corp) | Owned and managed hospitals, remote telehealth (to be demerged), project consultancy, O&M contracts |
Digital Health & Pharmacy Distribution | Apollo HealthCo Ltd (AHEL about 78.87% per Wikipedia; Advent 12.1% via CCPS) | Back-end distribution to Apollo Pharmacy stores, Apollo 24/7 platform, online pharmacy, insurance distribution |
Retail Health & Diagnostics | Apollo Health and Lifestyle Ltd (100% from Apr 2026) | Clinics, diagnostics, sugar clinics, Spectra, dialysis, dental; Cradle and Fertility pending divestment |
Segment revenue (INR Cr)
| Segment revenue (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Healthcare Services revenue (INR Cr) | 9,865 | 11,147 | 12,555 |
Apollo HealthCo revenue (INR Cr) | 7,839 | 9,093 | 10,808 |
AHLL revenue (INR Cr) | 1,363 | 1,554 | 1,865 |
Consolidated revenue (INR Cr) | 19,059 | 21,794 | 25,229 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Healthcare Services YoY growth (%) | — | 13 | 13 |
Apollo HealthCo YoY growth (%) | — | 16 | 19 |
AHLL YoY growth (%) | — | 14 | 20 |
Healthcare Services share of consolidated revenue (%) | 51.8 | 51.1 | 49.8 |
Apollo HealthCo share of consolidated revenue (%) | 41.1 | 41.7 | 42.8 |
AHLL share of consolidated revenue (%) | 7.2 | 7.1 | 7.4 |
Segment EBITDA (INR Cr)
| Segment EBITDA (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Healthcare Services EBITDA (INR Cr) | 2,349 | 2,701 | 3,063 |
Apollo HealthCo EBITDA post 24/7 costs and ESOP (INR Cr) | — | 168 | 493 |
AHLL EBITDA (INR Cr) | 117 | 154 | 213 |
Consolidated EBITDA (INR Cr) | 2,398 | 3,022 | 3,769 |
Segment EBITDA margin (%)
| Segment EBITDA margin (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Healthcare Services EBITDA margin (%) | 23.8 | 24.2 | 24.4 |
Apollo HealthCo EBITDA margin (%) | — | 1.8 | 4.6 |
AHLL EBITDA margin (%) | 8.6 | 9.9 | 11.4 |
Consolidated EBITDA margin (%) | 12.6 | 13.9 | 14.9 |
Results by Segment
| Segment PAT (INR Cr) | FY2025 | Q1 FY26 | Q1 FY27 |
|---|---|---|---|
Healthcare Services PAT (INR Cr) | 1,426 | 384 | 480 |
Apollo HealthCo PAT (INR Cr) | — | 57 | 101 |
AHLL PAT (INR Cr) | -27 | — | -1 |
Results by Segment (Q1FY26–Q1FY27)
| Quarterly metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Consolidated revenue (INR Cr) | 5,842 | 6,304 | 6,477 | 6,605 | 7,043 |
Healthcare Services revenue (INR Cr) | 2,935 | 3,169 | 3,183 | 3,268 | 3,567 |
Apollo HealthCo revenue (INR Cr) | 2,472 | 2,661 | 2,827 | 2,848 | 2,977 |
AHLL revenue (INR Cr) | 435 | 474 | 467 | 489 | 499 |
Consolidated EBITDA (INR Cr) | 852 | 941 | 965 | 1,011 | 1,092 |
Healthcare Services EBITDA (INR Cr) | 718 | — | — | 781 | 862 |
Apollo HealthCo EBITDA (INR Cr) | 94 | 110 | — | 156 | 171 |
AHLL EBITDA (INR Cr) | 40 | — | — | 75 | 59 |
Consolidated PAT attributable (INR Cr) | 433 | 477 | 502 | 529 | 581 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 14,663 | 16,612 | 19,059 | 21,794 | 25,229 |
Revenue YoY growth (%) | 38.9 | 13.3 | 14.7 | 14.3 | 15.8 |
EBITDA company-reported (INR Cr) | — | — | 2,398 | 3,022 | 3,769 |
EBITDA margin (%) | — | — | 12.6 | 13.9 | 14.9 |
Screener operating margin OPM (%) | 15 | 12 | 13 | 14 | — |
Net profit attributable to owners (INR Cr) | 1,056 | 819 | 899 | 1,446 | 1,942 |
Net margin (%) | 7.2 | 4.9 | 4.7 | 6.6 | 7.7 |
EPS basic (INR) | 73.42 | 56.97 | 62.50 | 100.56 | 135.07 |
EPS diluted (INR) | — | — | — | — | 134.95 |
Dividend per share declared (INR) | — | — | 16 | 19 | 20 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 13,269 | 14,428 | 16,753 | 20,657 | 22,197 |
Net PP&E incl. right-of-use (INR Cr) | 7,289 | 8,034 | 9,385 | 10,587 | 12,030 |
Goodwill (INR Cr) | 940 | 986 | 1,012 | 1,031 | 1,032 |
Cash and short-term investments (INR Cr) | 1,048 | 726 | 1,190 | 2,010 | 2,133 |
Long-term borrowings (INR Cr) | 2,427 | 1,938 | 2,236 | 4,417 | 2,430 |
Short-term borrowings (INR Cr) | 208 | 773 | 926 | 858 | 3,228 |
Total borrowings excl. leases (INR Cr) | 2,636 | 2,710 | 3,162 | 5,275 | 5,659 |
Total debt incl. lease liabilities (INR Cr) | 4,068 | 4,332 | 5,333 | 7,864 | 8,493 |
Net debt incl. leases (INR Cr) | 3,020 | 3,607 | 4,143 | 5,854 | 6,360 |
Net debt excl. leases (INR Cr) | 2,053 | 2,277 | 2,656 | 4,697 | 4,847 |
Shareholders' funds (INR Cr) | 5,623 | 6,197 | 6,935 | 8,212 | 9,480 |
Minority interest (INR Cr) | 280 | 334 | 385 | 441 | 494 |
Trade receivables (INR Cr) | 1,950 | 2,498 | 2,812 | 3,361 | 3,674 |
Inventory (INR Cr) | 432 | 390 | 460 | 481 | 542 |
Net working capital (INR Cr) | 1,738 | 1,012 | 615 | 2,450 | 419 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 1,696 | 1,377 | 1,920 | 2,136 | 2,856 |
Capital expenditure (INR Cr) | 657 | 1,129 | 1,137 | 1,712 | 1,962 |
Free cash flow (INR Cr) | 1,039 | 248 | 783 | 424 | 894 |
Cash acquisitions (INR Cr) | 101 | 50 | 4 | 0 | 1,300 |
Investing cash flow (INR Cr) | -847 | -871 | -1,537 | -3,381 | -2,148 |
Financing cash flow (INR Cr) | -792 | -633 | -311 | 1,317 | -478 |
Net debt issued or repaid (INR Cr) | -493 | -128 | 225 | 1,887 | 90 |
Interest paid (INR Cr) | 255 | 251 | 303 | 302 | 278 |
Income tax paid (INR Cr) | 204 | 382 | 467 | 486 | 606 |
Dividends paid derived (INR Cr) | — | — | 216 | 273 | 288 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 20.7 | 13.9 | 13.7 | 19.1 | 22.0 |
ROA on average assets (%) | 8.0 | 5.9 | 5.8 | 7.7 | 9.1 |
ROCE consolidated excl. CWIP company-reported (%) | — | — | 20.0 | — | 23.7 |
ROCE Screener (%) | 17 | 14 | 15 | 17 | — |
Debt to equity excl. leases (x) | 0.47 | 0.44 | 0.46 | 0.64 | 0.60 |
Net debt to EBITDA incl. leases (x) | — | — | 1.73 | 1.94 | 1.69 |
Net debt to EBITDA excl. leases (x) | — | — | 1.11 | 1.55 | 1.29 |
Interest coverage EBITDA to interest paid (x) | — | — | 7.9 | 10.0 | 13.6 |
Asset turnover on average assets (x) | — | 1.20 | 1.22 | 1.17 | 1.18 |
Cash conversion cycle Screener (days) | -12 | -14 | -16 | -23 | -6 |
Region revenue (INR Cr)
| Region revenue (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India consolidated revenue (INR Cr) | 19,059 | 21,794 | 25,229 |
India YoY growth (%) | 14.7 | 14.3 | 15.8 |
Cluster Datapoint Details
| Cluster datapoint (Q3 FY26) | Value |
|---|---|
Eastern region revenue growth YoY | +15% (IP volume +6%, ARPP +10% to INR 1,54,408; occupancy 76%) |
Highest-ARPP cluster cited | INR 2,02,804 at 68% occupancy across 1,355 beds |
Cluster with weakest occupancy cited | 51% occupancy (ARPP INR 1,66,264) |
Group occupancy | 67% vs 68% a year earlier, with 8,072 operating beds |
Datapoint Details
| Datapoint | Value | Source / date |
|---|---|---|
Last price | INR 7,739.50 | NSE, 19 Oct 2026 1:02 pm (ad-hoc-news) |
52-week range | INR 6,696.50 – 9,070.50 | ad-hoc-news, Oct 2026 (Anand Rathi high INR 9,326.80) |
1-year return | About +3.2% | Anand Rathi, 7 Oct 2026 |
3-year return | About +77.3% | Equentis, as of 10 Apr 2026 |
5-year return | About +139.8% | Equentis, as of 10 Apr 2026 |
10-year return | About +448% | Equentis, as of 10 Apr 2026 |
Beta | About 0.8 (Equentis); Tickertape describes volatility at 1.70x Nifty | Sources differ |
Valuation Multiples
| Multiple | Apollo | Basis |
|---|---|---|
Market cap (INR Cr) | 111,282 | 143.78 million shares |
Enterprise value (INR Cr) | 118,136 | Market cap + net debt incl. leases (INR 6,360 crore) + minority (INR 494 crore) |
P/E TTM (x) | 53.2 | TTM attributable PAT about INR 2,090 crore |
EV/EBITDA TTM (x) | 29.5 | TTM EBITDA about INR 4,009 crore |
EV/Sales TTM (x) | 4.5 | TTM revenue INR 26,430 crore |
P/B (x) | 11.7 | FY26 shareholders' funds INR 9,480 crore |
Analyst Ratings & Targets
| Broker | Date | Rating | Target (INR) |
|---|---|---|---|
Jefferies | 2 Oct 2026 | Buy | 10,350 |
Nomura | Aug 2025 | Neutral | — |
Simply Wall St aggregated consensus target | Date not specified (stale) | — | 8,793.5 |
ICICI Direct | 2026 | Buy (long-term) | — |
Dividend metric
| Dividend metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim dividend per share (INR) | — | — | 6 | 9 | 10 |
Final dividend per share (INR) | 11.75 | 9 | 10 | 10 | 10 |
Total dividend per share (INR) | — | — | 16 | 19 | 20 |
Payout ratio on attributable PAT (%) | — | — | 25.6 | 18.9 | 14.8 |
Credit Ratings
| Agency | Entity | Rating | Outlook | Date |
|---|---|---|---|---|
ICRA | AHEL (INR 3,000 crore term loans/unallocated) | AAA / A1+ | Stable | Assigned 12–18 May 2026 |
CRISIL | AHEL (INR 2,800 crore bank facilities; INR 19 crore NCDs) | AA+ / A1+ | Positive (revised from Stable, 27 Jan 2026) | Reaffirmed; credit bulletin 29 May 2026 |
CRISIL | Apollo HealthCo | AA- / A1+ | Watch Developing | Jan 2026 |
CRISIL | AHLL | AA- | Positive (upgraded from A+) | 27 Jan 2026 |
CRISIL | Apollo Multispeciality Hospitals | AA+ / A1+ | Positive | 27 Jan 2026 |
CRISIL | Apollo Hospitals North | AA / A1+ | Watch Positive | May 2026 |
Moody's / S&P / Fitch | AHEL | Not rated (not publicly disclosed) | — | — |
Analyst Conclusions
Management guidance (FY27)
Management has guided to:
-
Hospital revenue growth of about 18–20%, with at least 100 bps of HCS margin expansion.
-
An Apollo HealthCo/AHTL annualised revenue run-rate of INR 25,000 crore with a 6.5–7% exit EBITDA margin by Q4 FY27.
-
Apollo 24/7 full breakeven by Q3 FY27.
-
Gurugram commissioning in Q3 FY27.
-
AHTL listing in Q4 FY27.
Q1 FY27 delivered against this trajectory: HCS +22%, HealthCo EBITDA margin 5.8%, digital cash loss INR 10 crore.
Consensus growth expectations
Simply Wall St's analyst-consensus narrative (date unspecified) assumed about 17.5% annual revenue growth and a 9.1% profit margin by 2029. Q1 FY27 revenue of INR 7,044 crore beat consensus of INR 6,886 crore (ad-hoc-news).
Bull case
-
Pure-play re-rating. After demerger, AHEL becomes a hospital company with about 24–25% EBITDA margins and 25%+ ROCE plus a 15% stake in AHTL. Hospital peers trade at 60–66x P/E against Apollo's consolidated about 53x, so the blended-margin discount could close.
-
Earnings visibility from capacity. Census beds grew from 8,025 (Mar 2025) to 8,352 (Jun 2026) and are heading towards about 13,100. With established hospitals growing 13–14% plus about 7% from new hospitals, high-teens HCS growth can persist for several years.
-
HealthCo operating leverage. Quarterly EBITDA went from INR 36 crore (Q4 FY25) to INR 171 crore (Q1 FY27). Hitting a 6.5–7% margin on an INR 25,000 crore run-rate implies about INR 1,600–1,750 crore of annualised AHTL EBITDA, more than three times FY26's derived INR 493 crore.
Bear case
-
Regulatory compression. The NPPA oncology 30% trade-margin cap and Supreme Court scrutiny of hospital mark-ups directly hit pharmacy and consumable margins in Apollo's most complex specialty. Further caps on consumables or room/package pricing could erode the 24% HCS margin.
-
Execution overload. Simultaneously building 5,800 beds (about INR 11,150 crore), completing a three-way scheme, closing Cloudnine and merging AHNL stretches management. Start-up losses and refinancing of about INR 3,200 crore of current debt add risk.
-
Valuation and governance. At about 53x TTM P/E and 11.7x P/B the stock prices in success. Promoter selling (Aug 2025), a modest 28% promoter stake, and related-party optics in the Keimed merger could cap multiples.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| 27 Oct 2026 | Supreme Court hearing on drug and consumable mark-ups |
| 5 Nov 2026 | Q2 FY27 results: HCS growth vs 18–20% guidance; HealthCo margin; digital breakeven |
| Nov 2026 | NPPA notification of the oncology trade-margin cap (covered drugs, effective date) |
| Q3 FY27 (Oct–Dec 2026) | Gurugram hospital commissioning; Apollo 24/7 full breakeven |
| Q3–Q4 FY27 | NCLT final sanction of the composite scheme; Cloudnine closing |
| Q4 FY27 (Jan–Mar 2027) | Apollo Healthtech listing; AHEL receives 15% stake; shareholders receive 195.2 AHTL shares per 100 AHEL |
| FY27 | Refinancing of current borrowings; ICRA/CRISIL surveillance (possible CRISIL upgrade given Positive outlook) |
| Quarterly | Occupancy (70% in Q1 FY27), ARPOB/ARPP, new-unit losses, international patient trends, promoter pledge and shareholding |
Analyst verdict
Apollo Hospitals enters the second half of FY27 at the strongest operating point in its 43-year history. Consolidated revenue is running at about INR 28,000 crore annualised. Q1 FY27 growth of 21% was the fastest in several years. Consolidated EBITDA margins have widened about 230 bps in two years, and the balance sheet now carries the sector's only AAA rating. The improvement is broad: hospitals re-accelerated from single-digit growth to 22% as new capacity ramped, AHLL is compounding at about 20% with expanding margins, and Apollo HealthCo has turned from a cash drain into a contributor as Apollo 24/7 losses were nearly eliminated.
The investment debate is therefore less about operating quality than about structure, regulation and price. Structurally, the Apollo Healthtech demerger is the key value-realisation event. It separates a 24%-margin, 25%-ROCE hospital franchise from a mid-single-digit-margin distribution platform, and lets each be valued on its own terms. The cost is that the integration moat must now survive arm's-length contracts, and timing has already slipped once. On regulation, India's renewed push on oncology drug margins and hospital mark-ups is the most material external risk and is live within weeks. On price, about 53x trailing earnings and about 29x EV/EBITDA leave limited room for execution missteps across a 5,800-bed build.
Our synthesis is constructive on fundamentals and neutral-to-positive on timing. The earnings trajectory, credit quality and demerger optionality justify a premium to the Indian market. Near-term upside depends on clean delivery of the Q2–Q3 FY27 digital breakeven, Gurugram commissioning, and a contained outcome from the NPPA and Supreme Court proceedings. Investors should treat pricing-policy clarity in November 2026 and the AHTL listing in Q4 FY27 as the two gating events for a sustained re-rating toward pure-play hospital multiples.
APPENDIX — PRINCIPAL SOURCES CONSULTED
-
Apollo Hospitals Q4 FY26 earnings call transcript (apollohospitals.com, May 2026) — FY26 and Q4 figures, segment data, guidance
-
Apollo Hospitals Q2 FY26 earnings call transcript (apollohospitals.com, Nov 2025) — Q2 FY26 KPIs
-
Apollo Hospitals Q4 FY25 call (AlphaStreet transcript) and FY25 release (mediacdn.apollohospitals.com) — FY25 segment data
-
NSE filing: hospital expansion corrigendum (31 May 2025) — Expansion plan
-
NSE filing: Cloudnine press release (20 May 2026) — Divestment terms
-
NSE filing: ICRA rating letter (19 May 2026); ICRA rationale (18 May 2026) — Credit rating
-
CRISIL rating rationales (27 Jan 2026) and credit bulletin (29 May 2026) — Ratings, AHLL/Apollo Medicals transactions, AHNL merger
-
IIFL directors' report extract (composite scheme) — Scheme structure
-
Quartr Q1 FY27 and Q4 FY26 summaries; Kotak Neo; IPP (Indian Pharma Post); PTI via HDFC Sky; Stockgro — Q1 FY27 results and guidance
-
Alpha Spread / Yahoo Finance Q4 FY26 call; BW Healthcare World; Multibagg; Whalesbook; Investywise; ScanX — FY26 results, NCLT timeline, dividends
-
Outlook Business; HDFC Sky; Basis Point Insight; Sahi — Demerger terms and timeline
-
Business Standard; ICICI Direct research notes; FundsIndia; EY healthcare newsletters (Jan and Jul 2026) — Analyst views, capacity, industry context
-
Upstox; MarketsMojo; Emkay/Dion; Univest; Voguestock (shareholding) — Ownership
-
stockanalysis.com; Stockopedia; Stockezee; Screener; MarketsMojo (financial statements) — Five-year financials
-
Anand Rathi; Value Research; Fyers; Equentis; ICICI Direct; ad-hoc-news (Oct 2026) — Price, valuation, peers
-
Medical Dialogues; Outlook India; The South First; Moneylife (Oct 2026) — NPPA oncology cap, Supreme Court proceedings
-
Company press releases on Dr. Madhu Sasidhar's appointment (Mar 2024); Becker's Hospital Review — Leadership
-
Wikipedia (Apollo Hospitals; Indraprastha Apollo Hospital) — Historical milestones (secondary)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Education | Age |
|---|---|---|---|---|
Dr. Prathap C. Reddy | Founder & Executive Chairman | Founded Apollo 1983; cardiologist; Padma Vibhushan | MBBS (Stanley Medical College); US cardiology training | About 93 (b. 1933, per public biographies) |
Ms. Preetha Reddy | Executive Vice Chairperson | Long-standing executive director; formerly Managing Director | — | Not disclosed here |
Ms. Shobana Kamineni | Executive Vice Chairperson; Executive Chairperson of Apollo HealthCo; proposed Executive Chairperson of Apollo Healthtech Ltd upon NCLT sanction | Leads pharmacy/digital; former CII President | — | Not disclosed here |
Ms. Suneeta Reddy | Managing Director | MD of AHEL; leads finance and strategy | — | Not disclosed here |
Dr. Sangita Reddy | Joint Managing Director; Chairperson of AHLL | Former FICCI President; digital health and telemedicine lead | — | Not disclosed here |
Dr. Madhu Sasidhar | President & CEO, Hospitals Division | Joined Oct 2023 as Chief Strategy Officer; CEO since Mar 2024. Previously 16 years at Cleveland Clinic, including President of Tradition Hospital and CMO of Cleveland Clinic Abu Dhabi | MBBS (JIPMER); Internal Medicine (St Luke's-Roosevelt, New York); Pulmonary and Critical Care fellowships (Yale); Global Executive MBA (INSEAD) | — |
Mr. Krishnan Akhileswaran | Group Chief Financial Officer | Long-tenured CFO | — | — |
Mr. S. M. Krishnan | Senior Vice President – Finance & Company Secretary | Signatory on NSE/BSE filings | — | — |
Mr. Sriram Iyer | CEO, Apollo Health and Lifestyle Ltd | Named on FY25–FY26 earnings calls | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Oct 2023 | Dr. Madhu Sasidhar joins as Chief Strategy Officer | Planned succession for hospital leadership |
Mar 2024 | Sasidhar named President & CEO, Hospitals; Dr. K. Hari Prasad retires | Professionalisation of hospital operations |
May–Jun 2026 | Shobana Kamineni proposed as Executive Chairperson of Apollo Healthtech Ltd, effective on NCLT sanction | Governance of demerged NewCo |
Shareholding Trend
| Holder category (% of equity) | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|
Promoter and promoter group (%) | 29.34 | 28.02 | 28.02 | 28.02 | 28.02 |
Foreign institutional investors (%) | 43.49 | 44.20 | 43.54 | 42.62 | 41.5 |
Mutual funds (%) | 15.94 | 16.48 | 16.75 | 16.65 | — |
Other domestic institutions (%) | 5.41 | 4.65 | 4.75 | 6.11 | — |
Total DII (%) | — | — | — | 22.76 | 23.72 |
Retail and others (%) | 5.83 | 6.66 | 6.94 | 6.60 | — |
Major Shareholders
| Holder | Shares (lakh) | % stake |
|---|---|---|
PCR Investments Ltd (promoter entity) | 272.23 | 18.93 |
Ms. Suneeta Reddy | 29.37 | 2.04 |
Government of Singapore (largest public shareholder) | — | 2.34 |
Dr. Sangita Reddy | 24.33 | 1.69 |
Ms. Shobana Kamineni | 22.40 | 1.56 |
Mr. K. Vishweshwar Reddy | 15.77 | 1.10 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs Apollo |
|---|---|---|
Hospitals | Max Healthcare Institute | Highest-margin listed peer (about 27% EBITDA, ARPOB about INR 77,900); North India-centric; aggressive expansion |
Hospitals | Fortis Healthcare | Pan-India; owns Agilus diagnostics; about 24% hospital margin (Q2 FY26) |
Hospitals | Narayana Health | Value-cost model; Cayman and UK operations; strong ROE |
Hospitals | Global Health (Medanta) | NCR/Lucknow/Patna; ARPOB about INR 62,000 |
Hospitals | Aster DM Healthcare / Quality Care India | Post-merger South India platform; revenue +18% FY26 |
Hospitals | Manipal Hospitals | Large Bengaluru/East footprint; appears as a listed peer in Fyers data (Sep 2026) |
Hospitals | KIMS Hospitals | South India; expanding |
Hospitals | HCG (oncology) | Oncology-focused competitor in Bengaluru and beyond |
Pharmacy retail | MedPlus Health Services | Listed omnichannel pharmacy chain |
Pharmacy retail | Wellness Forever, Tata 1mg, PharmEasy, Netmeds (Reliance), Amazon Pharmacy | Online and offline competitors to Apollo Pharmacy and 24/7 |
Pharma distribution | Entero Healthcare and regional distributors | Competitors to Keimed |
Diagnostics | Dr Lal PathLabs, Metropolis, Agilus (Fortis), Thyrocare | Competitors to Apollo Diagnostics |
Maternity | Cloudnine, Rainbow Children's Medicare, Motherhood | Apollo exiting via Cloudnine stake |
Peer Comparison FY2026
| Metric | Apollo Hospitals | Max Healthcare | Fortis Healthcare | Narayana Health |
|---|---|---|---|---|
Market cap (INR Cr) | 124,661 | 95,868 | 68,701 | 37,993 |
TTM revenue (INR Cr) | 26,430 | 8,712 | 9,506 | 9,072 |
TTM net profit (INR Cr) | 2,127 | 1,457 | 1,052 | 824 |
Net margin (%) | 8.0 | 16.4 | 11.0 | 9.1 |
ROE (%) | 22.7 | 14.4 | 11.1 | 20.1 |
P/E (x) | 60.5 | 66.4 | 65.8 | 47.1 |
Hospital EBITDA margin Q2 FY26 (%) | 24.6 | 27 | 24 | 24 |
Consolidated EBITDA margin Q2 FY26 (%) | 15 | 27 | 24 | 24 |



